Journal article
Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome
TA Rasmussen, J McMahon, JJ Chang, J Symons, M Roche, A Dantanarayana, A Okoye, B Hiener, S Palmer, WS Lee, SJ Kent, C Van Der Weyden, HM Prince, PU Cameron, SR Lewin
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Abstract
Objective: To study the effects of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy (ART) with Sezary syndrome, a rare malignancy of CD4+ T cells. Design: Case report. Methods: Blood was collected 30 and 18 months prior to presentation with Sezary syndrome, at the time of presentation and during alemtuzumab. T-cell subsets in malignant (CD7-CD26-TCR-VBeta2+) and nonmalignant cells were quantified by flow cytometry. HIV-DNA in total CD4+ T cells, in sorted malignant and nonmalignant CD4+ T cells, was quantified by PCR and clonal expansion of HIV-DNA assessed by full-length next-generation sequencing. Results: HIV-hepatitis B virus coinfection was diagnose..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
The study was funded by the National Health and Medical Research Council (NHMRC) of Australia program grant (PI Lewin). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the article.